These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36338747)

  • 1. Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Zhang Y; Zhang L; Zhao Y; Wang S; Feng L
    Front Oncol; 2022; 12():945867. PubMed ID: 36338747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Walter A; Rocconi RP; Monk BJ; Herzog TJ; Manning L; Bognar E; Wallraven G; Aaron P; Horvath S; Tang M; Stanbery L; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2021 Dec; 163(3):459-464. PubMed ID: 34702567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
    Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2021 Jun; 161(3):676-680. PubMed ID: 33715892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
    Barve M; Aaron P; Manning L; Bognar E; Wallraven G; Horvath S; Stanbery L; Nemunaitis J
    Clin Med Insights Oncol; 2022; 16():11795549221110501. PubMed ID: 35957960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
    Rocconi RP; Stanbery L; Tang M; Madeira da Silva L; Walter A; Monk BJ; Herzog TJ; Coleman RL; Manning L; Wallraven G; Horvath S; Bognar E; Senzer N; Brun S; Nemunaitis J
    Commun Med (Lond); 2022; 2():106. PubMed ID: 36051466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.
    Nemunaitis J; Stanbery L; Walter A; Wallraven G; Nemunaitis A; Horvath S; Bognar E; Rao D; Engle S; Brun S; Ghisoli M; Rocconi RP; Monk BJ; Coleman RL
    Future Oncol; 2024; 20(29):2149-2164. PubMed ID: 39101448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.
    Rocconi RP; Stanbery L; Madeira da Silva L; Barrington RA; Aaron P; Manning L; Horvath S; Wallraven G; Bognar E; Walter A; Nemunaitis J
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
    Oh J; Barve M; Matthews CM; Koon EC; Heffernan TP; Fine B; Grosen E; Bergman MK; Fleming EL; DeMars LR; West L; Spitz DL; Goodman H; Hancock KC; Wallraven G; Kumar P; Bognar E; Manning L; Pappen BO; Adams N; Senzer N; Nemunaitis J
    Gynecol Oncol; 2016 Dec; 143(3):504-510. PubMed ID: 27678295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of survival and post-operation outcomes for minimally invasive versus open hepatectomy in hepatocellular carcinoma: A systematic review and meta-analysis of case-matched studies.
    Fu B; Zhang JR; Han PS; Zhang YM
    Front Oncol; 2022; 12():1021804. PubMed ID: 36338679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients.
    Xue C; Zheng S; Dong H; Lu X; Zhang X; Zhang J; Li J; Cui H
    Front Oncol; 2021; 11():627016. PubMed ID: 34513654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
    Sliheet E; Robinson M; Morand S; Choucair K; Willoughby D; Stanbery L; Aaron P; Bognar E; Nemunaitis J
    Cancer Gene Ther; 2022 Jul; 29(7):993-1000. PubMed ID: 34785763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
    Front Oncol; 2021; 11():732214. PubMed ID: 34557415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
    Front Oncol; 2022; 12():978069. PubMed ID: 36330494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with
    Ma J; Deng H; Li J; Hu S; Yang Y; Liu S; Han X
    Cancer Manag Res; 2019; 11():3061-3078. PubMed ID: 31114351
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials.
    Huang Q; Mei Z; Han X
    Front Oncol; 2022; 12():972767. PubMed ID: 36119468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Angiogenesis Maintenance Therapy in Newly Diagnosed and Relapsed Ovarian Cancer: A Meta-analysis of Phase III Randomized Controlled Trials.
    Wang Y; Zhang S; Song Z; Ouyang L; Li Y
    Front Pharmacol; 2021; 12():726278. PubMed ID: 34867330
    [No Abstract]   [Full Text] [Related]  

  • 18. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
    Guo C; Yan C; Qu L; Du R; Lin J
    Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
    Rocconi RP; Stevens EE; Bottsford-Miller JN; Ghamande SA; Elder J; DeMars LL; Munkarah A; Aaron P; Stanbery L; Wallraven G; Bognar E; Manley M; Horvath S; Manning L; Walter A; Galanis E; Herzog T; Monk BJ; Coleman RL; Nemunaitis J
    Cancer Gene Ther; 2022 Mar; 29(3-4):369-382. PubMed ID: 33753870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials.
    Xie M; Zhong Y; Yang Y; Shen F; Nie Y
    Front Oncol; 2022; 12():1039320. PubMed ID: 36387136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.